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ABSTRACT
Invasive fungal infections pose major management problems for clinicians caring for hematopoietic cell
transplant patients. Two major fungal genera, Candida and Aspergillus, account for most fungal infections.
Rates of systemic Candida infection range from 15% to 25%, mostly in the pre-engraftment period. Prophylaxis
by fluconazole has dramatically reduced the frequency of early Candida infections. Caspofungin has recently
been shown to offer an excellent alternative to amphotericin B (with less toxicity) or fluconazole (with a
broader spectrum) for therapy of systemic Candida infections. Aspergillus infections occur in 15% to 20% of
allogeneic hematopoietic cell transplant patients, most frequently in the post-engraftment period; they are
associated with a severe diminution of cell-mediated immune responses by graft-versus-host disease and
prolonged corticosteroid use. Voriconazole, a recently introduced broad-spectrum azole, has excellent activity
against Aspergillus and is generally well tolerated. Voriconazole currently offers the best prospect for success
and tolerance as a first-line treatment for aspergillosis. Second-line therapies include lipid formulations of
amphotericin B, caspofungin, or intravenous itraconazole. Unfortunately, early initiation of therapy for
aspergillosis is frequently not possible because of inaccurate diagnostics. One new diagnostic, the galactoman-
nan assay, has recently been approved, and others are in development; these offer promise for earlier diagnosis
without the need for invasive procedures. It is hoped that these new therapies and new diagnostics will usher
in a new era of antifungal therapy.
© 2004 American Society for Blood and Marrow Transplantation
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The 2 most difﬁcult challenges facing the clinician
aring for allogeneic hematopoietic cell transplant
HCT) recipients are graft-versus-host disease
GVHD) and infectious complications. Once cyto-
egalovirus (CMV) was the chief infectious threat,
ut today, invasive fungal infections (IFI) are the ma-
or causes of infectious morbidity and mortality after
llogeneic HCT. The change is due not only to a
iminution in serious CMV disease from the intro-
uction of new drugs and adoption of new prophylac-
ic or preemptive strategies, but also to an increase in
FI rates, changes in fungal epidemiology, and lack of
rogress in fungal therapeutic approaches.
A double peak in the occurrence of IFIs was noted
any years ago. The ﬁrst peak occurs during the ﬁrst
onth after HCT (the pre-engraftment interval). p
B&MTandida, a yeast, is part of the endogenous ﬂora of
atients and historically has been the most common
ungal pathogen during the pre-engraftment period.
ystemic invasion by colonizing Candida organisms
akes place with bacterial suppression by antibiotics
permitting fungal overgrowth), mucosal injury by in-
ensive conditioning regimens (allowing easier entry),
nd loss of second-line host defenses (phagocytosis
ompromised by neutropenia, and cell-mediated im-
unity suppressed by the immunosuppressive regi-
en and GVHD). Aspergillus, a mold, is an exog-
nously acquired pathogen that usually gains entry by
nhalation into nasal passages and the respiratory
ract. Aspergillus represents a distant second pathogen
uring the pre-engraftment period.
The second peak occurs in the postengraftmenteriod, chieﬂy during the second and third months.
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7VHD and the use of corticosteroids are the chief
isk factors. Aspergillus is the predominant pathogen in
his second peak; Candida and other mold pathogens
ccount for a minority of the other IFIs.
Other risk factors for IFIs have been identiﬁed.
se of more intensive conditioning regimens, prior
spergillosis, CMV infection, use of T-cell depletion
f the stem cell graft, use of cord blood as the source
f stem cells, and HLA mismatching of donor and
ecipient are among the risk factors noted in various
eries.
In recent years, a number of changes have oc-
urred in rates of infection, types of pathogens, and
ime course. Candida infections have dramatically de-
reased with the adoption of ﬂuconazole prophylaxis
uring the pre-engraftment period. Hematopoietic
rowth factors and the use of peripheral blood to
ptimize the CD34 cell content of the stem cell graft
ave shortened the time to engraftment. Reduced-
ntensity nonmyeloablative conditioning regimens
ave reduced the duration of neutropenia and the
egree of damage to the mucosa of the gastrointestinal
ract. These changes in transplantation practice have
ll combined to greatly reduce the risk for IFI (as well
s bacterial infections) during the pre-engraftment
eriod. In contrast, several changes in transplantation
ractice have combined to increase the risk for IFIs in
he postengraftment period. The increasing use of
lternate allogeneic donors, including matched unre-
ated donors, mismatched family donors, and cord
lood, and the reliance on more potent immunosup-
ressive regimens to suppress GVHD have increased
he risk for IFI after engraftment. The higher rates of
hronic GVHD after peripheral blood allografts have
een accompanied by more IFIs, along with other
nfectious complications. Today, more and more IFIs
re occurring after day 100, extending the duration of
ulnerability.
For autologous HCT recipients, certain events
efore transplantation place the patient at risk. Prior
FI is associated with an almost guaranteed exacerba-
ion during subsequent HCT. Potent purine analogs
lso increase the susceptibility for IFI by producing a
rofound, long-lasting deﬁciency of cell-mediated im-
unity. Events during the transplantation procedure,
ncluding CD34 cell selection of the stem cell graft
nd use of steroids during the peritransplantation pe-
iod, increase the susceptibility of autologous HCT
ecipients for IFI in the postengraftment period.
The effectiveness of ﬂuconazole prophylaxis in
eduction of Candida infections has shaped the fungal
herapy map for a decade. Although concerns were
aised nearly a decade ago that emergence of ﬂucon-
zole resistance would mitigate the effectiveness of
andida prophylaxis, that fear has fortunately largely
emained unrealized. Scattered reports of several out-
reaks of Candida infections have been noted in HCT p
4atients receiving ﬂuconazole because of resistant
andida species (Candida krusei and C. glabrata) and
lso because of ﬂuconazole-sensitive species (C. parap-
ilosis), yet these have been largely isolated. Shifts to
on-albicans Candida species have occurred, but the
et effect of ﬂuconazole has been an enormous reduc-
ion in the more prevalent C. albicans and C. tropicalis
pecies; this net decrease to date has overshadowed the
maller increase in the non-albicans species.
Although Candida infections have decreased, As-
ergillus infections have relentlessly increased in fre-
uency. Aspergillus species once infected only 4% to
% of allogeneic HCT recipients, but today rates of
2% to 15% are regularly being reported, and even
igher rates have been observed in some centers and
n some subgroups of high-risk patients. Although it
as hoped that nonmyeloablative allogeneic trans-
lants would be associated with fewer infections, a
ecrease in IFIs has not been realized in several re-
orted series. In part, the high rate of IFI after non-
yeloablative allogeneic transplantations is related to
he more aggressive tapering of immunosuppressive
herapy in many such regimens that is designed to
aximize the potential for graft-versus-tumor effects.
any of the early series also were composed of high-
isk patients with multiple failed attempts to control
he underlying disease or a higher tumor burden at the
ime of transplantation or of frail patients with mul-
iple comorbidities. With time, as regimens are stan-
ardized and lower-risk groups undergo transplanta-
ion, this may change.
Infections from other mold pathogens have also
ncreased, including Zygomycetes and Fusarium species,
ut still these are relatively infrequent. Infections due
o Scedosporium species have remained infrequent.
The time of onset has gradually been pushed to
ater times. The apparent increase in late-onset IFI is
n part attributable to the abrogation of the initial
re-engraftment peak from Candida, but it is also
ttributable to the greater occurrence of chronic
VHD with peripheral blood grafts and to an in-
rease in older patients receiving transplants. This
ater onset frequently takes place after the patient has
eft the transplant center, which poses additional chal-
enges for close monitoring and vigilance for longer
eriods and often at great distances from the trans-
lant center.
HE DRUGS
There are 4 classes of licensed drugs for therapy of
FIs. These include polyenes (the various formulations
f amphotericin B), nucleoside analogs (ﬂucytosine),
zoles (ﬂuconazole, itraconazole, and voriconazole),
nd echinocandins (caspofungin). Several of these
rugs have established roles, and others have shown
romise in HCT patients.
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Advances in Antifungal Therapy
Bolyenes
Amphotericin B deoxycholate. Amphotericin B de-
xycholate has the longest track record as an antifun-
al agent. Its mechanism of action is binding to sterols
n the fungal cell membrane (Table 1). After it binds
o ergosterol, leakage of intracellular univalent and
ivalent cations and subsequent cell death follow. This
gent is preferentially more toxic to the fungal cell
embrane than to the mammalian cell membrane
ecause of its selectivity for ergosterol (in fungi) over
holesterol (in mammalian cells). Resistance to am-
hotericin B occurs infrequently but seems to take
lace by alteration in the ergosterol content in the
ungal cell membrane [1,2].
Amphotericin B has the widest spectrum of activ-
ty against fungi, with activity against most human
able 1. Mechanisms of Action of Different Antifungal Agents
Class Fungal Target A
olyene Ergosterol Binding to ergo
lucytosine Nucleic acid synthesis Inhibition of nu
zoles Ergosterol Inhibition of er
chinocandins  (1, 3) glucan synthetase Inhibition of glu
able 2. Pharmacologic Comparison of Most Commonly Used Agents
Characteristic Amphotericin B Fluconazole
ormulation IV PO, IV
east activity Yes Yes
old activity Yes No
alf-life (h) ? 30
oading dose No No
sual maintenance dose 0.5-1 mg/kg 400 mg
requency of dosing Daily Daily
ioavailability of oral
absorption
NA >90%
oute of elimination Renal, fecal Hepatic metabo
renal excretio
NS penetration Yes# Yes
A indicates not applicable; IV, intravenous; PO, orally; CNS, cen
Aspergillus only.
Alpha half-life.
Beta half-life.
Gamma half-life.
Inﬂamed meninges; poor penetration in uninﬂamed meninges.
Clinical relevance not certain.
B&MTungal pathogens, including most Candida and As-
ergillus species. Amphotericin B was introduced 50
ears ago; its efﬁcacy was not tested in controlled
rials, but for many years it was the only antifungal
reatment option (see reviews [3,4]). Notwithstanding
ts wide spectrum of activity, there are several notable
xceptions. Strains of C. lusitaniae, C. guilliermondii,
richosporon beigelli, A. terreus, some strains of A. ﬂa-
us, Fusarium species, Pseudallescheria boydii, and Sce-
osporium species are relatively resistant, and treat-
ent outcomes are poor.
The pharmacokinetics of amphotericin B are
oorly understood (Table 2). Much of the adminis-
ered dose of amphotericin is deposited in tissues,
specially fat, and a depot effect is notable with a slow
elease into the blood long after cessation of admin-
Mechanism of Resistance
Altered or decreased amounts of ergosterol
in cell membrane; defects in sterol
biosynthetic pathways
cid synthesis Mutations in cytosine deaminase; decrease in
uracil phosphoribosyl transferase activity
l biosynthesis Mutations in ERG11, CDR1, CDR2, MDR1;
overexpression of efflux pumps;
overexpression/mutations of target
enzyme
osynthesis No data
Itraconazole Voriconazole Caspofungin
PO, IV PO, IV IV
Yes Yes Yes
Yes Yes Yes*
30-40 PO 35 IV 6 1-2†/9-11‡/40-50§
Yes
200 mg PO TID 
3 d or 200 mg
IV BID  4 d
Yes
6 mg/kg IV
Q12h  2 doses
or 400 mg PO
Q12h  2 doses
Yes
70 mg  1 d
200 mg 200 mg 50 mg
Every 12 h Every 12 h Daily
55% (solution) 96% NA
Hepatic Hepatic Hepatic
No Yes No
rvous system.ction
sterol
cleic a
gostero
can bilism,
n
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7stration. Excretion occurs in urine and feces. Ampho-
ericin B doses of approximately 0.5 to 0.75 mg/kg/d
re generally sufﬁcient to treat most Candida infec-
ions. Breakthrough Aspergillus infections have been
oted in patients receiving amphotericin B doses of
.5 mg/kg/d. Higher doses, in the range of 1 to 1.5
g/kg/d, are necessary for treatment of Aspergillus and
ther mold infections.
Toxicities are frequent with amphotericin B. In-
usional reactions include fever and rigors that occur
n approximately half of all treated patients and, less
requently, hypotension, wheezing, hypoxia, and rash.
lder age and rapid infusions are factors associated
ith a greater propensity for infusional reactions. Pre-
edication with acetaminophen and diphenhydra-
ine is frequently given to minimize the troubling
eactions, but no controlled studies have demon-
trated their effectiveness. Hydrocortisone and ibu-
rofen, in contrast, have been shown in controlled
rials to reduce the reactions, although they are infre-
uently used because steroids may attenuate the effec-
iveness of antifungal therapy and ibuprofen is contra-
ndicated in patients with thrombocytopenia.
ortunately, tachyphylaxis typically occurs, with or
ithout premedication, and after 4 to 6 days the re-
ctions tend to abate. Severe rigors can be treated with
5 to 50 mg of meperidine, although this agent should
e avoided in patients with renal dysfunction because
f accumulation of the neurotoxic metabolite (norme-
eridine), which may result in seizures.
Nephrotoxicity is a major limitation of the clinical
sefulness of amphotericin B. The risk for nephrotox-
city varies in different series. Risk factors include the
ean daily dose (35 mg), the duration of the treat-
ent course, chronic renal disease, and the use of
oncomitant nephrotoxins such as cyclosporine and
minoglycosides. Slower infusions seem to be associ-
ted with reduced rates of nephrotoxicity [5-7]. Severe
ephrotoxicity resulting in hemodialysis is associated
ith death [8,9] and results in higher utilization of
ealth resources, prolonged hospital duration, and
reater costs [8,10]. Even lower levels of nephrotox-
city, such as a doubling of the serum creatinine, are
imilarly associated with greater health-care resource
tilization [11].
Saline loading has been shown to reduce the risk
or nephrotoxicity [12]. Mannitol has not been proven
o be useful [13]. Dopamine and sodium bicarbonate
ave been suggested to be protective against nephro-
oxicity in preclinical models [14,15], but these have
een evaluated in few clinical trials [16].
Other toxicities include anemia, electrolyte wast-
ng by renal tubules (potassium, magnesium, and bi-
arbonate), hepatic dysfunction, seizures, and an-
rexia. One small study suggested that amiloride
rotected against amphotericin B–induced potassium I
6asting or at least reduced the daily potassium-re-
lacement requirements [17].
The high rates of nephrotoxicity with amphoter-
cin B in allogeneic HCT patients receiving cal-
ineurin inhibitors have severely limited the ability of
ransplant clinicians to use amphotericin B in the
herapy of IFIs. Thus, alternatives have been sought as
igh priorities for supportive-care measures.
Lipid formulations of amphotericin B. Lipid formu-
ations of amphotericin B were developed to provide a
ess toxic formulation of amphotericin B. Three lipid
ormulations have been licensed in the United States:
mphotericin B lipid complex (ABLC), amphotericin
in colloidal dispersion (ABCD), and liposomal am-
hotericin B (see reviews [4,18-23]). These agents all
ave the same antifungal spectrum of activity as am-
hotericin B deoxycholate.
The pharmacokinetic properties differ between
he formulations, and interesting differences in tissue
istribution of amphotericin B have been noted. Li-
osomal amphotericin B has been associated with sub-
tantially higher levels of amphotericin B in the brains
f experimentally infected animals [24]. Autopsy anal-
sis of amphotericin B tissue levels suggests substan-
ially higher levels of amphotericin B in the lung after
BLC administration [18]. To date, the clinical sig-
iﬁcance of these observations has not been elucidated
see discussion [23]). Preclinical data suggest that
igher concentrations of the lipid formulations com-
ared with the deoxycholate formulation are needed
o exert similar antifungal effects (see review [4]).
ortunately, the agents have substantially greater tol-
rability, permitting higher doses in clinical practice,
nd doses of 4 to 6 mg/kg/d were chosen for treatment
f IFIs in most clinical trials.
All of the lipid formulations have been found in
andomized trials to have substantially less nephrotox-
city than amphotericin B deoxycholate, even though
ubstantially higher doses were used (4-6 mg/kg/d)
25-32] (Table 3). In 2 controlled trials comparing the
oxicity of ABLC and liposomal amphotericin B when
sed as empirical therapy for neutropenic fever, lipo-
omal amphotericin B was associated with less neph-
otoxicity than ABLC [33,34]. Most of the differences
een between the 2 products were in mild degrees of
ephrotoxicity, but there was also a smaller, but sig-
iﬁcant, difference in moderately severe nephrotoxic-
ty. There were no differences in the rates of hemo-
ialysis occasioned by severe nephrotoxicity, which
as very infrequent with both products.
Infusional toxicities are less frequent with liposo-
al amphotericin B compared with amphotericin B
eoxycholate [35] and with ABLC [34]. However,
ven with liposomal amphotericin B, there are infu-
ional reactions, especially ﬂank, chest, or back pain,
hich can occur in approximately 5% of patients [36].
nfusional reactions with ABCD are either similar to
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Br greater than those with amphotericin B deoxy-
holate [31,32].
Controlled trials of the amphotericin B lipid for-
ulations with amphotericin B deoxycholate have not
hown convincing superiority in response or survival
ates in the ﬁrst-line treatment of Candida [28], As-
ergillus [31], or Cryptococcus [27,29], but liposomal
mphotericin B was found to be superior to ampho-
ericin B deoxycholate against histoplasmosis in hu-
an immunodeﬁciency virus–infected individuals [26]
Table 3). Despite no clear demonstration of superi-
rity in efﬁcacy, the advantages in safety and reduc-
ions in health-care resource utilization realized by the
paring of nephrotoxicity that offset much of the
dded cost of the drug, as well as the frank intolerance
f amphotericin B deoxycholate, have led many HCT
linicians to abandon amphotericin B deoxycholate in
avor of one of the lipid formulations [4]. Different
linicians have placed different weights on how much
oncern they place on infusional toxicities, how much
ncremental difference in nephrotoxicity they are will-
ng to tolerate, and how much difference in price they
re willing to bear in the choice of which lipid formu-
ation to choose (see discussion [23]).
Dose schedules in controlled trials have varied
onsiderably. Generally speaking, doses of 4 to 6 mg/
g/d have been used for the treatment of documented
FIs, whereas lower doses (1-3 mg/kg/d) have been
tudied in trials of empirical antifungal therapy for
eutropenic fever. Only 1 trial has studied what dose
chedule is optimal for the treatment of documented
nfection. Ellis et al. [37] evaluated liposomal ampho-
ericin B in a randomized trial of 2 doses (1 and 4
g/kg/d). Patients were required to have probable or
roven invasive aspergillosis. No differences in either
esponse rate or survival were seen, but it is important
o note that the sample size was very small and the
tatistical power to detect a difference (if present) was
nadequate to reject the null hypothesis; moreover, the
esponse rate for proven infections in the 4 mg/kg/d
roup was higher than in the 1 mg/kg/d group (58%
ersus 37%). Many experts believe that this trial is
nconclusive for recommending a lower-dose schedule
or the therapy of invasive aspergillosis.
Lower-dose schedules were tested for empirical
able 3. Comparison of Lipid Amphotericin B Formulations with Amp
Author Pathogen Agent
naissie [28] Candida ABLC
owden [31] Aspergillus ABCD
eenders [30] Mixed L-amph
amill [27] Cryptococcus L-amph
eenders [29] Cryptococcus L-amph
ohnson [26] Histoplasmosis L-amph
BLC indicates amphotericin B lipid complex; ABCD, amphotericntifungal therapy for neutropenic fever [25,32,34,35]. c
B&MThese empirical therapy studies do not provide sub-
tantial evidence for efﬁcacy differences between for-
ulations; however, they do indicate that doses of 1 to
mg/kg/d are effective for empirical therapy, and they
rovide an excellent source of toxicity information. In
ne study, the toxicity of liposomal amphotericin B in
oses of 3 and 5 mg/kg/d was not substantially differ-
nt [34]. In another trial, liposomal amphotericin B
iven at 1 mg/kg/d was slightly less effective in defer-
escence than at a dose of 3 mg/kg/d [25]. Most
vidence seems to suggest that the dose chosen should
e governed by the indication for use rather than
hich lipid formulation is chosen: doses for docu-
ented infections range from 4 to 6 mg/kg/d, and
oses for empirical antifungal therapy for suspected
FI during neutropenic fever range from 1 to 3 mg/
g/d.
yrimidine Analogs
Flucytosine is a pyrimidine analog that is trans-
orted by cytosine permease into susceptible fungi
nd then deaminated to the active form (5-ﬂuoroura-
il), which subsequently interferes with fungal nucleic
cid synthesis. Candida and Cryptococcus species are
enerally susceptible. Most molds (including Aspergil-
us) are resistant. As a single agent by itself, rapid
evelopment of resistance occurs through alteration in
ytosine permease or altered metabolism [38]. Thus,
ts role has been relegated to an adjunctive role, and it
as been most widely embraced as part of combination
herapy of cryptococcal meningitis, along with am-
hotericin B. In vitro assays have suggested an addi-
ive effect to amphotericin B against Candida and As-
ergillus species, but to date no clinical trial data have
onﬁrmed this.
Flucytosine is available only as an oral agent.
oses of 50 to 150 mg/kg/d (in divided doses every 6
ours) are generally used. The dose should be reduced
n the presence of renal dysfunction. As noted, ﬂucy-
osine is metabolized to ﬂuorouracil, which is myelo-
uppressive and causes damage to the gastrointestinal
ucosa. Thus, its use has been quite limited in the HCT
etting. Moreover, because of variable bioavailability,
evels should be monitored to avoid toxicity; blood
B Deoxycholate as First-Line Therapy of Invasive Fungal Infections
Response Survival Toxicity
Same Same Less
Same Same Less
Same Same Less
Same Same Less
Same Same Less
Improved Improved Less
lloidal dispension; L-amp, liposomal amphotericin.hotericin
in B cooncentrations should be maintained 100 g/mL.
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7zoles
The mechanism of action of the azole class of
ntifungals is inhibition of fungal cytochrome P450
4--sterol demethylase and of 24-methylene dihy-
rolanosterol demethylation (Table 1). These en-
ymes are key in the biosynthesis of ergosterol. With
nhibition of the conversion of lanosterol to ergos-
erol, accumulation of lanosterol occurs, and there is a
eduction of ergosterol in the fungal cell membrane,
eading to inhibition of fungal growth. There are
everal azoles licensed for clinical use, and they differ
y molecular structure according to speciﬁc side
hains that lead to differences in pharmacologic prop-
rties, toxicity proﬁles, and spectra of activity. There
re also several azoles in the investigational pipeline
hat are moving closer to commercial availability.
Fluconazole. Most Candida species are highly sus-
eptible to ﬂuconazole (deﬁned as minimal inhibitory
oncentration 8 mg/L) [39]. However, several spe-
ies are not reliably controlled by ﬂuconazole. C. kru-
ei is natively resistant to ﬂuconazole. Isolates of C.
labrata are less susceptible to ﬂuconazole and are
enerally classiﬁed as susceptible-dose dependent,
eaning that higher concentrations are necessary for
n vitro inhibition (minimal inhibitory concentration,
6 to 32 mg/L) rather than for susceptible isolates.
ome C. glabrata strains are frankly resistant (64
g/L). C. dubliniensis isolates are also resistant to ﬂu-
onazole. Fortunately, C. krusei and C. dubliniensis
nfections are infrequent. However, C. glabrata infec-
ions account for 10% to 20% of all invasive Candida
nfections in various series, and these seem to be
ncreasing over time. This increase seems coincident
ith the use of ﬂuconazole, suggesting the pressures
f selection of less susceptible fungal organisms. Re-
ssuringly, bloodstream isolates of C. albicans have
emained largely susceptible to ﬂuconazole a decade
fter its introduction into clinical practice [40].
Resistance to ﬂuconazole occurs through several
echanisms (see reviews [1,41]): alteration of the tar-
et enzyme (14--sterol-demethylase) by mutation or
verexpression of ERG11 or upregulation of efﬂux
ransporters (encoded by CDR1, CDR2, and MDR1
enes). Emergence of resistance to C. albicans has been
een largely in patients with advanced acquired immu-
odeﬁciency syndrome with very low (and declining)
D4/T-lymphocyte counts, to whom prolonged ad-
inistration of low doses (50-200 mg/d) of ﬂucon-
zole was given for oropharyngeal candidiasis. This
xperience has contrasted with the experience in leu-
emia and HCT patients, in whom shorter courses of
igher doses (400 mg/d) were given and in whom
estoration of host defenses (neutrophil recovery, re-
overy of cell-mediated immune responses, or both)
enerally occurred. It seems likely that these different
rajectories of host differences are important in un- d
8erstanding the reasons for these different experi-
nces. Notwithstanding, as noted previously, several
utbreaks of Candida bloodstream infections by ﬂu-
onazole-resistant organisms have been reported in
CT patients receiving ﬂuconazole prophylaxis [42-
4]. Fortunately, these have been infrequent, and un-
ublished data exploring these outbreaks suggest that
common source may have been contributory. How-
ver, the resistance story in advanced human immu-
odeﬁciency virus infection should serve as a caution-
ry note for potential similar concerns that may
ertain to patients with poor T-cell immune reconsti-
ution after HCT.
All of the azoles are metabolized by the liver and
re inhibitory to hepatic cytochrome P450 isoen-
ymes. Not surprisingly, there are considerable drug-
rug interactions with a multitude of other drug
lasses that are metabolized by hepatic cytochrome
450 enzymes (Tables 4 and 5). These are too numer-
us to describe in detail, but transplant clinicians
hould be mindful of the potentiation of calcineurin
nhibitors by azoles. The degree of potentiation differs
ccording to the azole. For example, there is an ap-
roximately 20% increase in cyclosporine levels with
uconazole 400 mg but an approximately 50% in-
rease in cyclosporine levels with itraconazole and
oriconazole. For voriconazole, the increase in cyclo-
porine levels is similar to that caused by itraconazole,
ut the increase in tacrolimus levels is even greater.
The ﬁrst-generation azoles—clotrimazole, keto-
onazole, and ﬂuconazole—have excellent activity
gainst Candida species. Multiple controlled trials have
hown these agents to be effective as therapy for oro-
haryngeal candidiasis. Because of a lack of systemic
ffect, clotrimazole is used only for mucosal infec-
ions. Ketoconazole, the ﬁrst systemic azole, has
argely been replaced by ﬂuconazole because of vari-
ble bioavailability and dependence on gastric acidity
or maximal absorption.
Fluconazole is available as both an oral and intra-
enous formulation and has excellent bioavailability
90%) independent of gastric acidity (Table 2). The
rug half-life is approximately 30 hours, facilitating
nce-daily dosing. Fluconazole is metabolized by cy-
ochrome P450 3A4 isoenzymes in the liver and the
astrointestinal tract and is excreted renally. Dose
djustments are necessary when the creatinine clear-
nce decreases to 50 mL/min. Routine dosage ad-
ustments are not required for liver dysfunction; how-
ver, if hepatic transaminases increase in the presence
f ﬂuconazole, this may represent drug-induced tox-
city. The standard dose of ﬂuconazole in the treat-
ent of Candidamucosal infections is generally 100 to
00 mg/d. For candidemia caused by susceptible Can-
ida species, doses of 400 mg are recommended, with
he exception of C. glabrata species, for which higher
oses of up to 800 mg/d may be necessary. For chil-
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Advances in Antifungal Therapy
Bren, dosing for serious Candida infections is 6 mg/
g/d.
Fluconazole has a favorable safety proﬁle com-
ared with other antifungal agents and is well toler-
ted, with few severe toxicities. One of the most com-
on toxicities is an increase in hepatic transaminases.
ther side effects include nausea and vomiting (at the
igher doses) and rashes. Because of the hepatic me-
abolism, ﬂuconazole is subject to several drug inter-
ctions, where it may increase the serum concentra-
ion of concomitantly administered medications;
able 4. Clinically Relevant Drug Interactions with Systemic Antifung
oncomitantly Administered Drug
Type of Drug
Interactions
Fluconazole Itracona
PK PK
oncomitant drug
whose serum
concentration is
increased by the
antifungal
agents
All trans-retinoic acid
Antihistamines
(astemizole, terfenadine)
Benzodiazepines (eg,
midazolam, triazolam)
Calcineurin inhibitors (ie,
cyclosporine, tacrolimus)
Carbamazepine
HMG CoA reductase
inhibitors (eg,
simvastatin)
Hypoglycemic agents (eg,
glimepiride)
Opioids (eg, alfentanil)
Phenytoin
Rifamycins (eg, rifampin,
rifabutin)
Sirolimus
Warfarin
Antiarrhythmics
dofetilide, quin
Antihistamines
(astemizole, te
Antineoplastic a
vinca alkaloids
cyclophospham
docetaxel, eto
Benzodiazepines
midazolam, tr
Calcineurin inhib
cyclosporine, t
Cisapride*
Coicosteroids
(oral/inhaled/IV
Digoxin
HMG CoA redu
inhibitors (eg,
atorvastatin, l
simvastatin)*
Opioids (eg, fent
Pimozide*
Quinidine
Sirolimus
Warfarin
K indicates pharmacokinetics; PD, pharmacodynamics; CYP, cyto
intravenous; NNRTI, non-nucleoside reverse transcriptase inhi
Contraindicated.
Interaction hypothesized on the basis of metabolism.
Data derived from in vitro studies.
able 5. Clinically Relevant Drug Interactions with Antifungal Agents
Variable Fluconazole Itr
oncomitant drugs that
decrease serum
concentrations of systemic
antifungal agents
Phenytoin
Rifabutin
Rifampin
Ph
Rif
Rif
Contraindicated per package insert.
Interaction hypothesized on the basis of metabolism.
Data derived from in vitro studies.
B&MTonversely, its own concentration may be altered by
he concomitantly administered drug (Tables 4 and 5).
Fluconazole is highly active against Candida iso-
ates. There is also activity against Cryptococcus species,
istoplasmosis, and coccidiomycosis. Randomized tri-
ls and case-controlled studies have shown ﬂuconazole
o be highly effective as therapy of systemic Candida
nfections (Table 6), with response and survival rates
omparable to those of amphotericin B [45,46]. Time
o clearance of Candida bloodstream infections is sim-
lar although slightly slower than with amphotericin
ts Resulting in an Increase in the Serum Concentration of the
Voriconazole Amphotericin B
PK PD
)
ine*)
eg,
fan,
)
ral
)*
eg,
us)
in,*
Antihistamines (astemizole,
terfenadine)*†
Antineoplastic agents†
(metabolized via
CYP3A4, 2C9, and 2C19
isoenzymes)
Benzodiazepines‡
Calcineurin inhibitors
(cyclosporine, tacrolimus)
Calcium channel blockers‡
(dihydropyridine class)
Ergot alkaloids*
HMG CoA reductase
inhibitors‡
Hypoglycemic agents‡
NNRTIs‡
Omeprazole
Phenytoin
Protease inhibitors‡
Rifamycins (rifabutin,
rifampin)1
Sirolimus*
Warfarin
Aminoglycosides
Antineoplastic agents (eg,
cisplatin, bleomycin)
Cidofovir
Calcineurin inhibitors
(cyclosporine, tacrolimus)
Flucytosine
Foscarnet
e P450; HMG CoA, 3-hydroxy-3-methylglutaryl coenzyme A; IV,
of Other Drugs on the Pharmacokinetics of Antifungal Agents
ole Voriconazole Amphotericin B
Barbiturates (long acting)*†
Carbamazepine†
NNRTIs‡
Phenytoin
Protease inhibitors‡
Rifabutin*
Rifampin*
Nilal Agen
zole
(eg,
idine*
rfenad
gents (
, busul
ide,
poside
(eg, o
iazolam
itors (
acrolim
)
ctase
ovastat
anyl)
chrom
bitors.: Effects
aconaz
enytoin
ampin
abutin79
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Wingard and Leather
8. It is important to note that most of these clinical
rials were conducted in nonneutropenic patients, and
here continues to be a paucity of data in neutropenic
atients. Thus, many experts continue to recommend
se of amphotericin B as preferable to ﬂuconazole in
reatment of the neutropenic patient with systemic
andidiasis.
Itraconazole. This azole has activity not only
gainst Candida and Cryptococcus species, histoplasmo-
is, blastomycosis, and coccidiomycosis, but also
gainst Aspergillus species. Two reviews of treatment
ractices of aspergillosis have illustrated its utility
47,48]. Unfortunately, there is a paucity of controlled
rials of itraconazole in the therapy of invasive Candida
nd Aspergillus infections; thus, it is unclear as to how
t compares with amphotericin B.
Itraconazole is less reliably and less well absorbed
y mouth (55% for the solution and much less for the
ral capsule) and has substantial interpatient variabil-
ty. The intravenous formulation is well tolerated.
traconazole demonstrates nonlinear pharmacokinet-
cs; thus, small increases in dose can lead to signiﬁ-
antly increased serum concentrations. Itraconazole is
etabolized primarily by the cytochrome P450 3A4
soenzyme system and therefore is also subject to a
umber of drug interactions with other medications
Tables 4 and 5). Itraconazole oral solution can be
ifﬁcult to tolerate, especially in the presence of mu-
ositis. Itraconazole also has substantial negative ino-
ropic effects. These cardiac effects can be particularly
roblematic in patients who have received anthracy-
lines or in those receiving concomitant high-dose
yclophosphamide. Although itraconazole is metabo-
ized by the liver, its intravenous formulation is sus-
ended in cyclodextrin, which is cleared by the kid-
eys. Accordingly, it should be avoided in patients
ith renal impairment (creatinine clearance 30 mL/
in). The oral formulation can be prescribed irre-
pective of creatinine clearance.
Voriconazole. Voriconazole has the broadest anti-
ungal spectrum of all the licensed azole antifungals
49-53]. In clinical trials, responses have been noted in
spergillus, Candida (including ﬂuconazole-resistant
andida species), Fusarium, and Scedosporium infec-
able 6. Randomized Comparative Trials for Therapy of Systemic Can
Study Fluconazole Amphoteric
ex [46] 70 79
naissie [28] 68
hillips [45] 50 56
ex [84] 56
ora-Duarte [62] 56
The combination of amphotericin B with ﬂuconazole.ions. A major gap in its coverage is a lack of activity t
0gainst Zygomycetes. A randomized trial comparing
mphotericin B and voriconazole as ﬁrst-line therapy
f invasive aspergillosis demonstrated voriconazole to
e more effective than amphotericin B, with higher
esponse rates and better overall survival [54]. In ad-
ition, voriconazole was associated with fewer toxici-
ies and greater tolerance. Some have criticized this
tudy, believing that a lipid amphotericin B would
ave been a fairer comparison. One can only speculate
hether that would have changed the results, but, as
oted previously, the only randomized comparison
etween a lipid amphotericin and amphotericin de-
xycholate did not show an improvement in either
esponse or survival [31].
Voriconazole avoids some of itraconazole’s short-
omings. It has excellent bioavailability (96%), with-
ut dependence on gastric acidity (Table 2). There are
o deleterious inotropic effects, unlike with itracon-
zole. The intravenous formulation’s excipient is a
yclodextrin, as with itraconazole, although it is a
ifferent molecule. Accordingly, as with itraconazole,
ntravenous voriconazole should be avoided in pa-
ients with compromised renal function (creatinine
learance 50 mL/min). When oral voriconazole is
rescribed, no dosage modiﬁcation is required for
enal insufﬁciency. For individuals aged 12 years,
he pharmacokinetics are nonlinear. For children un-
er the age of 12 years, the kinetics are linear and
learance is more rapid, necessitating higher doses to
chieve areas under the curve similar to those of older
atients [55]. Voriconazole penetrates the cerebrospi-
al ﬂuid and has documented activity in cerebral fun-
al infections, including disseminated Fusarium spe-
ies infections and disseminated Aspergillus infections
56].
There are 2 unique toxicities with voriconazole
hat are not typically seen with other azoles. One is
hotopsia, a visual disturbance manifested as a visual
alo, light aura, or blurring of visual objects. This
ccurs in 15% to 45% of patients in clinical trials,
ypically 30 to 60 minutes after the drug is adminis-
ered (either orally or intravenously), lasts 30 to 60
inutes, is most frequent early after the start of ther-
py, and usually abates over time. Despite this, pa-
fections
% Success
Combination* ABLC Caspofungin
63
68
66dida In
in Bients should be advised not to drive at night while
t
p
i
c
o
i
a
v
o
b
C
u
b
s
p
P
m
s
b
c
c
E
i
i
s
t
a
t
v
s
t
a
w
i
s
t
r
w
w
i
s
c
a
i
a
t
g
a
o
d
i
P
t
s
w

h
o
O
n
T
i
t
c
d
s
D
p
m
t
m
u
c
o
h
p
w
f
c
t
n
m
r
m
7
d
c
r
i
s
p
b
s
A
T
o
T
p
t
Advances in Antifungal Therapy
Baking voriconazole, and, similarly, they should avoid
otentially hazardous tasks if they perceive any change
n vision. A second reaction is photosensitivity, which
an occur in up to 5% of patients given the drug in the
utpatient setting. Neither reaction is severe, results
n permanent dysfunction, or necessitates discontinu-
tion of the drug.
One of the most important considerations with
oriconazole is the potential for drug interactions to
ccur (Tables 4 and 5). Voriconazole is metabolized
y 3 cytochrome P450 isoenzymes: CYP3A4,
YP2C9, and CYP2C19. Many of the commonly
sed drugs in immunocompromised patients have
een evaluated in pharmacokinetic drug interaction
tudies before Food and Drug Administration ap-
roval.
One other triazole is in clinical development.
osaconazole, currently available only in an oral for-
ulation, is in phase III clinical trials. Its antifungal
pectrum seems to be similar to that of voriconazole,
ut additionally it is active against the agents of mu-
ormycosis, in contrast to voriconazole. It does not
ause the visual changes seen with voriconazole.
chinocandins
The mechanism of action of the echinocandins is
nhibition of  (1,3)-glucan synthase, which leads to
nterference in the synthesis of glucan, a major con-
tituent of the fungal cell wall and a unique fungal
arget. Reduced glucan makes the fungal cell vulner-
ble to osmotic lysis.
Caspofungin. This is the only licensed member of
his family of antifungals. Caspofungin has excellent in
itro activity against Candida (including azole-resistant
pecies) and Aspergillus species [51,52,57-59]. In vitro
esting studies have raised concerns of lower activity
gainst several non-albicans Candida species, but
hether these in vitro ﬁndings are clinically important
s unclear because the clinical responses for these
pecies seem to be comparable to those with ampho-
ericin B. It was ﬁrst licensed on the basis of clinical
esponses noted in patients with invasive aspergillosis
ho had not responded to amphotericin B or who
ere intolerant of amphotericin B [60]. Two random-
zed trials, one in Candida esophagitis and the other in
ystemic candidiasis, have demonstrated excellent
linical activity [61,62] comparable to that of ﬂucon-
zole and amphotericin B, with substantially less tox-
city than amphotericin B. Caspofungin is not active
gainst Cryptococcus. There is little information as to
he activity of this agent against other fungal patho-
ens.
Caspofungin is poorly absorbed orally and is avail-
ble only in an intravenous formulation. The half-life
f the drug is 12 to 16 hours, permitting once-daily
osing. Dose adjustments are not needed in renal p
B&MTmpairment or in mild hepatic insufﬁciency (Child-
ugh score of 5 or 6) but should be adjusted in pa-
ients with moderate hepatic impairment (Child-Pugh
core of 7-9). There are no published data in patients
ith severe hepatic insufﬁciency (Child-Pugh score of
9). To date, the emergence of antifungal resistance
as not been observed in clinical practice for therapy
f Candida and Aspergillus infections.
Few toxicities have been noted with caspofungin.
ne notable caveat is an increase in hepatic transami-
ases seen in healthy volunteers given cyclosporine.
his did not result in severe sequelae and was revers-
ble on withdrawal, but this has necessitated a warning
hat clinicians should use caspofungin in patients re-
eiving concomitant cyclosporine only if the beneﬁt is
eemed more important than the risk. Cyclosporine
eems to increase caspofungin blood levels up to 30%.
osing in children is still being worked out, although
reliminary results indicate that a dose of at least 1
g/kg is required, and computer modeling suggests
hat dosing on the basis of body-surface area achieves
ore predictable blood concentrations (Walsh TJ,
npublished observations, 2003).
Two other echinocandins are in clinical trials. Mi-
afungin seems to have a similar antifungal spectrum
f activity and toxicity proﬁle as caspofungin [63]. No
epatic transaminase increases have been noted in
atients receiving micafungin and cyclosporin, unlike
ith caspofungin. Anidulafungin is in clinical trials.
Biologics. In vitro experiments indicate that anti-
ungal agents in combination with phagocytic host
ells have additive effects [64-69]. Attempts to exploit
hese observations have been made by using exoge-
ous cytokines to boost these effects. Such experi-
ents suggest that agents such as granulocyte-mac-
ophage colony-stimulating factor and -interferon
ay have salutary effects against Aspergillus [64,68,70-
5]. To date, there are insufﬁcient clinical trial data to
etermine whether these are clinically important. Ac-
ordingly, consensus panels do not recommend their
outine use. Another modality potentially useful in
nfected neutropenic patients is granulocyte transfu-
ions. With granulocyte colony-stimulating factor
riming of a donor, large numbers of granulocytes can
e obtained, and administration to recipients can have
ubstantial boosts in the circulating neutrophil count.
necdotal evidence suggests a possible beneﬁt [76-78].
hese have been generally well tolerated. Again, lack
f controlled trials makes the role of these unclear.
HE STRATEGIES
As important as the drugs we use are for the
rospects for success, the manner in which we use
hem is also extremely important. Three general ap-
roaches have been used: treatment, empirical therapy
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Wingard and Leather
8or suspected infection, and prophylaxis for those at
igh risk for IFI. The reason the last 2 have been
onsidered is the generally poor outcomes with treat-
ent regimens. Studies have demonstrated the utility
f such approaches in HCT and other situations [79-
2]. These comments will focus on approaches to
andida and Aspergillus infections only.
reatment
A number of treatment studies have been con-
ucted for Candida and Aspergillus infection, and these
ave formed the basis for treatment guidelines by
onsensus panels [39,83]. These must be interpreted
n the light of recent studies that likely alter some of
hose recommendations formulated 4 years ago.
Candida. Most experts recommend the removal of
he central venous catheter or any other foreign body
n an infected patient whenever possible [39] because
rugs often do not effectively penetrate bioﬁlms on
lastic surfaces harboring organisms. There are sev-
ral excellent options for antifungal therapy supported
y randomized trials (Table 6). Amphotericin B has
istorically been the gold standard. Intolerance and
he potential for severe nephrotoxicity makes it an
npalatable choice in patients receiving calcineurin
nhibitors [9]. ABLC has been shown to be as effective
s amphotericin B, with considerably less toxicity [28].
ccordingly, a lipid formulation would be preferable
o amphotericin B deoxycholate. Caspofungin is an-
ther excellent choice [62], but caution is necessary if
he patient is receiving cyclosporine, as noted previ-
usly. One option is to switch cyclosporine to tacroli-
us if the clinician wishes to use caspofungin and
eems a change in calcineurin inhibitor acceptable.
luconazole would be inappropriate for a patient who
evelops candidemia while receiving ﬂuconazole pro-
hylaxis, but it would be an excellent choice for a
atient who was not receiving ﬂuconazole and the
solate is susceptible [45,46]. The risk that one may be
reating a nonsusceptible Candida pathogen is the ma-
or factor that one should weigh in deciding whether
uconazole is appropriate for initial therapy. Often,
able 7. Randomized Comparative Trials for Therapy of Invasive Aspe
Author Test Agent Comparator
llis [37] L-amph 1 mg/kg L-amp 4 mg/kg
owden [31] ABCD 6 mg/kg Amph (1-1.5 mg/kg)
erbrecht [54] Vori 6 mg/kg LD,
then 4 mg/kg
every 12 h
Amph (1-1.5 mg/kg)
-amp indicates liposomal amphotericin B; ABCD, amphotericin B
azole; LD, loading dose.
P  .05.everal days pass from notiﬁcation of a positive culture h
2efore the isolate is speciated. Susceptibility testing is
ot widely available at present, and testing (even if it is
vailable) adds even more time. Knowledge of the
pecies provides a good estimate of susceptibility, with
. krusei, C. glabrata, and C. dubliniensis not reliably
usceptible and all others susceptible [39]. Accord-
ngly, one option is to start with a lipid amphotericin
or caspofungin and, once the organism is speciated
nd the patient stabilizes, change to ﬂuconazole for
usceptible isolates to complete therapy. One study
as evaluated combination therapy for candidemia in
onneutropenic patients [84] and is discussed below.
The duration of therapy is problematic, and there
s no clear guidance from published literature. Gen-
rally, one should continue treatment until resolution
f signs and symptoms, clearance of cultures, im-
rovement of radiologic manifestations, and improve-
ent of the host defenses that contributed to the
nfection.
Aspergillus. Early detection and prompt initiation
f antifungal therapy are key. Although amphotericin
deoxycholate has been the gold standard, it is poorly
olerated in allogeneic HCT patients, and success
ates are poor. The lipid amphotericin B products are
referable in the allogeneic HCT patient (for toler-
nce reasons), but results are not convincingly better
n terms of success or survival [31] (Table 7). There
re no controlled ﬁrst-line treatment trials with itra-
onazole or caspofungin. Recently, voriconazole fol-
owed by other licensed antifungal therapy (for pa-
ients with intolerance or lack of response) was found
o be superior to amphotericin B deoxycholate in
erms of response, survival, and tolerance, both overall
nd in the HCT subgroup [54]. Accordingly, voricon-
zole currently offers the best prospect for success and
olerance, on the basis of clinical trial data for ﬁrst-line
herapy. A lipid amphotericin B is an acceptable alter-
ative for those who cannot receive voriconazole be-
ause of intolerance; when it is used, it should be given
t a dose of 4 to 6 mg/kg/d. For patients whose
nfection progresses with voriconazole, one of the
ipid amphotericin B products, caspofungin, or per-
Infections
Response Rates Survival Rates
est Agent Comparator Test Agent Comparator
64% 48% 78% 80%
35% 35% 64% 55%
52.8%* 31.6%* 70.8% 57.9%
al dispersion; Amph, amphotericin B deoxycholate; Vori, voricon-rgillus
T
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Advances in Antifungal Therapy
Bions. In addition to pharmacologic therapy, resection
f localized infracted tissue should be considered (see
elow) [83].
mpirical Antifungal Therapy
Two small controlled trials of amphotericin B
85,86] demonstrated the capability of empirical anti-
ungal therapy to reduce fungal infections in neutro-
enic patients with persistent unexplained fever not
esponsive to antibiotics (Table 8). Initially, ampho-
ericin B was begun after 7 days of antibiotics, but in
uccessive studies, the start of antifungal therapy was
ushed earlier to 3 to 4 days of persistent fever, al-
hough no study has convincingly documented the
eed for an earlier start. Because of the considerable
oxicity of amphotericin B, as noted previously, alter-
atives to amphotericin B have been evaluated in con-
rolled trials. In subsequent trials of empirical antifun-
al therapy in which 2 active treatments were
ompared, the primary end point most commonly
sed has been “success”: a composite of several pa-
ameters, including defervescence, absence of break-
hrough IFI, survival, and absence of toxicity requiring
iscontinuation of the study drug. The problem with
nterpretation of the results of such trials is that suc-
ess is inﬂuenced by multiple factors, many of which
ay have nothing to do with IFIs. The rates of doc-
mented IFIs generally are too low (because active
rug is used in both arms and therapy is started early
n neutropenia) to determine relative efﬁcacy from
hese trials. Typically, more information is gained
bout relative toxicity proﬁles than about comparative
fﬁcacy from empirical therapy studies.
Lipid formulations of amphotericin B (ABCD and
iposomal amphotericin B) have demonstrated similar
able 8. Comparison of Various Antifungal Agents Used as Empirical
nfections
Author* Test Agent
Control
Comparator
izzo [86] Amph No antifungal
ORTC [85] Amph No antifungal
hite [32] ABCD Amph
alsh [35] L-amph Amph
oogaerts [87] Itra Amph
alsh [88] Vori L-amph
ingard [34] ABLC L-amph (3/5)‡
leming [33] ABLC L-amph
rentice [25] L-amph (1/3)‡ Amph
mph indicates amphotericin B deoxycholate; ABCD, amphoterici
azole; Itra, itraconazole; EORTC, European Organization for R
rials in which ﬂuconazole was the comparator were excluded, bec
Proven infection rates only: when combining both probable and p
Two doses of study drug (mg/kg/d), each evaluated in separate ar
P  .05.uccess rates as amphotericin B, with considerably less o
B&MToxicity [32,35] (Table 2). Intravenous itraconazole
as been compared with amphotericin B for persistent
eutropenic fever [87]; there was a trend toward a
igher rate of success with itraconazole. Voriconazole
as compared with liposomal amphotericin B; success
as slightly less frequent with voriconazole, but fewer
reakthrough IFIs occurred with voriconazole [88].
ecently, caspofungin has also been shown to provide
suitable alternative, with less toxicity than liposomal
mphotericin B [89].
rophylaxis
Amphotericin(s). Leukemic patients with prior As-
ergillus infections almost uniformly experience reac-
ivated infection on further antileukemic therapy or
ubsequent HCT once they are in remission. In the
ast, the extremely high case fatality rate led many
enters to exclude such patients from consideration
or HCT. The use of treatment doses of amphotericin
(1 mg/kg/d) as secondary prophylaxis allowed suc-
essful further antileukemic treatment and HCT
ithout exacerbation [90]. Primary prophylaxis (for
atients without prior IFI) with lipid amphotericin
roducts has been studied in only a limited manner;
rials that have evaluated liposomal amphotericin B
ave been too small to adequately test this strategy
91].
Low doses of amphotericin B have also been tested
or primary prophylaxis [92,93], but this approach
rovides protection only against Candida and not
gainst Aspergillus. Because ﬂuconazole is more toler-
ble for this purpose, this approach is not widely used.
Fluconazole. Prospective randomized trials have
emonstrated the effectiveness of ﬂuconazole prophy-
axis in HCT recipients when it is given from the start
during Neutropenic Fever Suspected to Be Caused by Invasive Fungal
Success Rates
Rates of Documented
Emergent IFIs
Agent Control Test Agent Control
stated Not stated 5.5% 31%
9% 53% 1.5% 9.4%
0% 43% 3.1% 3.2%
0% 49% 3.2%† 7.8%†
7% 38% 2.6% 2.6%
6% 31% 1.9% 5%
3% 40%/42% 3.8% 3.6%/2.5%
3%§ 39%§ Not stated Not stated
/64%§ 49%§ 2.6%/1.7% 2%
loidal dispersion; L-amph, liposomal amphotericin; Vori, voricon-
and Treatment of Cancer; ABLC, amphotericin B lipid complex.
CT patients are given ﬂuconazole prophylaxis.
IFIs, 4.95% versus 8.7%.Therapy
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894,95]; it reduces invasive Candida infection rates
rom 16% to 3%. In one trial, prolonged administra-
ion (until day 75) not only had a similar antifungal
eneﬁt, but also was associated with a survival advan-
age [96] that persisted even beyond the cessation of
uconazole [97]. Initial studies evaluated a dose of 400
g/d, but one study demonstrated that 200 mg/d was
lso effective [98]. Emergence of resistance has not
een reported. However, isolated reports of outbreaks
f ﬂuconazole-resistant organisms, such as C. krusei
nd C. glabrata, have been reported in several HCT
enters [42-44]. Fluconazole prophylaxis has been en-
orsed by consensus guidelines developed by the Cen-
ers for Disease Control, the American Society of
lood and Marrow Transplantation, and the Infec-
ious Disease Society of America [99].
Itraconazole. Two studies have evaluated itracon-
zole as long-term antifungal prophylaxis after alloge-
eic BMT, with the goal of reducing not only Candida
ut also Aspergillus infections [100,101]. In 1 of the 2
traconazole trials [100], a reduction in IFIs was noted
in comparison to ﬂuconazole), but there were inade-
uate numbers of Aspergillus cases to determine how
ffective it was as a prophylaxis against aspergillosis.
f concern, there was an excess of deaths (29.5%
ersus 18%) and of adverse events (6 versus 1), and
his led to discontinuation of the drug in the itracon-
zole group. The second randomized trial comparing
traconazole and ﬂuconazole [101] used a higher dose
f itraconazole to ensure therapeutic blood concen-
rations. The trial was stopped prematurely after
early 300 patients were enrolled (substantially more
nrollees than in the earlier study) because of excessive
oxicity in the itraconazole arm. A signiﬁcant excess of
enal and hepatic toxicity was noted in the patients in
he itraconazole arm. Thirty-six percent of patients
aking itraconazole stopped the drug because of tox-
city. There was no reduction in the frequency of
ungal infections in the itraconazole arm, although in
post hoc subset analysis of those who were able to
olerate it, there were fewer infections in the itracon-
zole arm. Taking both itraconazole HCT trials to-
ether, there currently are insufﬁcient data to state
eﬁnitively that itraconazole is safe and effective in the
llogeneic BMT setting for long-term prophylaxis.
Micafungin. This as-yet unlicensed echinocandin
as tested in a randomized comparison with ﬂucon-
zole as prophylaxis in HCT patients during the pre-
ngraftment period [102]. It was found to offer pro-
ection similar to that of ﬂuconazole against IFIs and
ewer persistent unexplained febrile episodes requir-
ng empirical trials of amphotericin B. It was well
olerated. There were too few Aspergillus infections to
scertain its protective capability against that patho-
en. i
4nfection-Control Measures
Candida organisms are generally endogenous,
ommensal colonizers of skin and mucosal surfaces;
ost infections arise from the patient’s own ﬂora.
owever, some studies have suggested patient-to-pa-
ient transmission in hospital environments (presum-
bly by health-care workers) in units housing trans-
lant recipients, leukemia patients, intensive care unit
atients, and surgical patients. Thus, hand washing is
n important facet of infection control. Outbreaks of
nfections in which nosocomial transmission is a pos-
ibility should be investigated by the hospital infec-
ion-control team. Molecular testing for DNA poly-
orphisms can be quite useful to determine whether 1
r more strains are present in multiple patients [103].
oint sources of infection that have been identiﬁed in
nvestigations of outbreaks include intravenous solu-
ions, medications, and plastic tubing.
Because Aspergillus conidia are exogenous organ-
sms present in the environment and are primarily
irborne, transmission of organisms can occur in the
ospital environment during construction, renova-
ion, or other activities in which organisms can be
pread and inhaled by susceptible immunocompro-
ised patients. Accordingly, high-efﬁciency air ﬁltra-
ion is important in hospital rooms in which highly
usceptible patients reside, to prevent outbreaks.
hese include HCT recipients, and the routine use of
igh-efﬁciency particulate air ﬁlters is recommended
n consensus guidelines [99]. The use of high-efﬁ-
iency masks worn during transport when patients
eave their rooms may also be helpful [104]. Recently,
atient shower facilities have been implicated as po-
ential sources of nosocomial Aspergillus acquisition
105,106]. Avoidance or cleaning procedures have
een proposed to reduce the risk to susceptible pa-
ients [107].
djunctive Therapies
Surgical excision should be considered in patients
ith pulmonary Aspergillus infections in which cavi-
ary or necrotic tissues are persistent or in which
esions are centrally located and catastrophic hemor-
hage may occur because of invasion of the pulmonary
asculature [83]. Catheter removal should be
romptly undertaken for all candidemic patients if
ossible [39,108]. Several studies suggest more rapid
learance of organisms from the bloodstream with
atheter removal, although a recent survey noted the
imitations of the data on which this recommendation
s based and suggested that clinical judgment be used
o identify those in whom the catheter should be
etained, taking into consideration the risks of its
emoval and its potential beneﬁts [109]. C. parapsilosis
s frequently associated with vascular catheters, and
c
p
N
N
m
s
i
w
s
w
b
s
t
t
o
t
h
b
d
t
a
c
b
p
t
n
s
t
i
w
d
g
m
i
a
t
U
t
a
I
b
r
s
I
t
i
a
t
w
s
M
t
n
d
f
i
a
w
(
m
c
g
t
p
w
t
v
u
b
f
m
v
i
w
r
i
p
c
p
o
f
t
t
q
t
2
f
i
i
h
i
p
t
o
a
e
s
r
w
C
Advances in Antifungal Therapy
Batheter removal is especially important for this
athogen.
EW DIRECTIONS
ew Diagnostics
Treatment outcomes have been severely compro-
ised by the inability to make the diagnosis early and
tart therapy promptly. The evidence for this is largely
ndirect. Outcomes for Candida infections are poorer
hen tissue sites are involved as well as the blood-
tream, and poorer outcomes are evident in patients
ith greater physiological compromise, as measured
y acute physiology and chronic health evaluation
cores. For Aspergillus infections, involvement of more
han 1 organ site is associated with poorer outcomes
han involvement of only 1 site. Moreover, outcomes
f Aspergillus infections identiﬁed early, as evident by
he presence of early radiologic manifestations (the
alo sign on chest computed tomographic scan), are
etter [110].
For these reasons, the development of new rapid
iagnostics has been a high priority for improving
reatment outcomes. Serologic assays are clinically
vailable for cryptococcosis, histoplasmosis, and coc-
idiomycosis, but until recently no similar assays have
een available for Candida and Aspergillus infections.
The galactomannan assay has been recently ap-
roved for use in the diagnosis of Aspergillus infec-
ions. This double sandwich enzyme-linked immu-
osorbent assay detects the concentration of the
oluble galactomannan antigen, which is present in
he circulation of patients with invasive Aspergillus
nfections, and compares the optical density index
ith that of a known positive serum; a calculated index
etermines positivity. Receiver operator curves sug-
est that an optical density index of 0.5 is optimal for
ost circumstances [111]. The test has been available
n Europe for years, but it has only recently been
pproved for use in the United States. It is important
o note that the threshold of positivity of the licensed
S test is set lower than that of the European licensed
est. True positivity necessitates repeating the assay,
nd the index must exceed 0.5 on 2 determinations.
nitially, 2 separate specimens were required for this,
ut data indicate that most of the false positives can be
esolved by merely repeating the test on the same
pecimen. If the test is negative, no repeat is required.
n data presented to the Food and Drug Administra-
ion, sensitivity in the diagnosis of invasive Aspergillus
nfections was approximately 80%, and speciﬁcity was
lso approximately 80%. In a prospective evaluation of
he assay in Europe in allogeneic HCT patients in
hom the test was performed twice weekly, the sen-
itivity and speciﬁcity were approximately 90% [112].
ost importantly, in nearly two thirds of infections, a
B&MThe assay was positive before currently available diag-
ostic methods with clinical, radiologic, and other
iagnostic tools. The test is recommended to be per-
ormed twice weekly during the period of vulnerabil-
ty. Certainly, this is a welcome addition to the tools
vailable to the clinician.
Positivity of the galactomannan assay also occurs
ith infections caused by Penicillium and Alternaria
true positives), but the rarity of those pathogens
eans that it is fairly speciﬁc for aspergillosis. Con-
erns have been raised questioning the utility of the
alactomannan assay in speciﬁc circumstances. Pa-
ients receiving antimold agents empirically or pro-
hylactically may develop invasive Aspergillus infection
ith galactomannan levels in the blood below the
hreshold of positivity in the licensed test [111]. De-
elopment of antibody by some patients may limit its
sefulness in such patients [113]. The test has not yet
een adequately studied in children.
The galactomannan assay has also been evaluated
or detection of Aspergillus antigens in other speci-
ens, including cerebrospinal ﬂuid and bronchoal-
eolar ﬂuid specimens. The early results are promis-
ng, but more data are needed to clarify whether these
ill be useful in clinical practice. Further, although
eporting of the commercial test results will be qual-
tative (positive or negative), quantitative results may
rove to be more informative, with the degree of
hange giving additional information that may im-
rove the performance of the assay. Moreover, testing
f serum specimens obtained after the start of anti-
ungal therapy may also provide early information as
o the likelihood of response or whether alternative
reatment should be considered. These questions re-
uire more investigation.
Another assay, the -glucan assay, is in clinical
esting [114] (Ostrosky-Zeichner L, unpublished data,
003). This antigen is broadly expressed in multiple
ungal genera. Thus, it can provide complementary
nformation to the galactomannan assay, which is lim-
ted to just Aspergillus among pathogens common to
umans in the United States and Europe. Its sensitiv-
ty and speciﬁcity are currently being evaluated in
rospective testing.
Several polymerase chain reaction assays that de-
ect fungal gene products present in a broad spectrum
f fungal pathogens have been tested [115]. In 1 case,
polymerase chain reaction assay was used to guide
mpirical antifungal therapy, and this resulted in a
paring of febrile patients not infected by fungi from
eceiving antifungal agents [115]. Additional trials
ith this technology are required.
ombination Therapy
Early studies found that combination therapy with
mphotericin B plus ﬂucytosine was more effective
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8han monotherapy with amphotericin B for crypto-
occal meningitis. Unfortunately, despite some in
itro data suggesting that combining amphotericin B
ith rifampicin or ﬂucytosine may be more effective
or Aspergillus or Candida, there have been no conﬁr-
atory clinical results.
In vitro susceptibility assays demonstrate additive
r synergistic activity of polyenes plus echinocandins
gainst Aspergillus [116,117]. Similarly, in vitro assays
uggest additive effects of voriconazole plus an echi-
ocandin [118]. Animal models that have tested com-
inations suggest that the in vitro observations may
ranslate into an in vivo beneﬁt [119-123]. Notwith-
tanding, the animal models have had to test the drugs
n subtherapeutic doses. Whether similar additive ef-
ects are also present when both drugs are used at full
oses is not known. There is a paucity of clinical data
n which combination therapy has been compared
ith monotherapy [124,125]. Accordingly, at present,
t is not possible to discern whether combination ther-
py is better than monotherapy, and it is generally not
ecommended [126]. It is important to recognize that
ot all combinations are additive, and some may in
act be antagonistic [127-131]. Accordingly, cautious
valuation of this promising topic is necessary.
There is 1 notable exception to these cautions. Rex
t al. [84] evaluated combination therapy for the treat-
ent of candidemia in nonneutropenic adults, com-
aring amphotericin B plus ﬂuconazole versus high
oses (800 mg/d) of ﬂuconazole alone. There was a
onsigniﬁcant trend to higher success rates with the
ombination therapy compared with monotherapy
69% versus 56%; P .08) and better clearance of the
loodstream infection by the combination therapy
P  .02). Unfortunately, there was also more toxicity
ith the combination therapy, and this mitigated the
et beneﬁt.
ONCLUSIONS
IFIs are a leading cause of morbidity and mortality
fter HCT. New drugs (voriconazole and caspofungin)
nd new formulations of older drugs (the lipid formula-
ions of amphotericin B and intravenous itraconazole)
ave expanded our therapeutic options, permitting safer
ormulations (lipid formulations of amphotericin B),
ore reliable drug delivery (intravenous formulation of
traconazole), broader spectra of activity (oral and intra-
enous formulations of voriconazole), and novel mech-
nisms of action (caspofungin). Knowledge of speciﬁc
pectra of activity of the various agents and recognition
f toxicities attendant to the speciﬁc agents are both
ecessary in choosing which agent is optimal for speciﬁc
athogens in different patient circumstances. A high
tate of vigilance is necessary for early detection—a job
erhapsmade easier by new diagnostics (the galactoman-
6an assay). It is hoped that these new drugs and new
etection methods will usher in a new generation of
ntifungal therapy that will result in improved outcomes.
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